Neuropathic Pain Pipeline Review H2 2011

Document Sample
Neuropathic Pain Pipeline Review H2 2011 Powered By Docstoc
					Neuropathic Pain – Pipeline Review, H2 2011




                 Neuropathic Pain - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1320IDB

                                                                                          Publication Date: September 2011




Neuropathic Pain – Pipeline Review, H2 2011                                                                   GMDHC1320IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                 Page(1)
Neuropathic Pain – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        6
List of Figures                                                                                                       9
Introduction                                                                                                         10
     Global Markets Direct Report Coverage                                                                           10
Neuropathic Pain Overview                                                                                            11
Therapeutics Development                                                                                             12
     An Overview of Pipeline Products for Neuropathic Pain                                                           12
Neuropathic Pain Therapeutics under Development by Companies                                                         14
Neuropathic Pain Therapeutics under Investigation by Universities/Institutes                                         19
Late Stage Products                                                                                                  23
     Comparative Analysis                                                                                            23
Mid Clinical Stage Products                                                                                          24
     Comparative Analysis                                                                                            24
Early Clinical Stage Products                                                                                        25
     Comparative Analysis                                                                                            25
Discovery and Pre-Clinical Stage Products                                                                            26
     Comparative Analysis                                                                                            26
Neuropathic Pain Therapeutics - Products under Development by Companies                                              27
Neuropathic Pain Therapeutics - Products under Investigation by Universities/Institutes                              35
Companies Involved in Neuropathic Pain Therapeutics Development                                                      38
     Bristol-Myers Squibb Company                                                                                    38
     Genzyme Corporation                                                                                             38
     Johnson & Johnson                                                                                               39
     Kyowa Hakko Kirin Co., Ltd.                                                                                     39
     Abbott Laboratories                                                                                             40
     Biogen Idec Inc.                                                                                                40
     Allergan, Inc.                                                                                                  41
     NsGene A/S                                                                                                      41
     Sanofi-Aventis                                                                                                  42
     AstraZeneca PLC                                                                                                 42
     BioDelivery Sciences International, Inc.                                                                        43
     GlaxoSmithKline plc                                                                                             43
     Nektar Therapeutics                                                                                             44
     Quark Pharmaceuticals, Inc.                                                                                     44
     Dainippon Sumitomo Pharma Co., Ltd.                                                                             45
     Sangamo BioSciences, Inc.                                                                                       45
     ZARS Pharma, Inc.                                                                                               46
     BioLineRx, Ltd.                                                                                                 46
     Daewoong Pharmaceutical Co., Ltd.                                                                               47
     Eisai Co., Ltd.                                                                                                 47
     Glenmark Pharmaceuticals Ltd.                                                                                   48
     Orion Corporation                                                                                               48
     Pfizer Inc.                                                                                                     49
     EpiCept Corporation                                                                                             49
     Evotec Aktiengesellschaft                                                                                       50
     GW Pharmaceuticals plc                                                                                          50


Neuropathic Pain – Pipeline Review, H2 2011                                               GMDHC1320IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(2)
Neuropathic Pain – Pipeline Review, H2 2011


     Anavex Life Sciences Corp.                                                                                      51
     IntelGenx Technologies Corp.                                                                                    51
     AVANIR Pharmaceuticals                                                                                          52
     Lpath, Inc.                                                                                                     52
     MediciNova, Inc.                                                                                                53
     Medivir AB                                                                                                      53
     NeurogesX, Inc.                                                                                                 54
     NicOx SA                                                                                                        54
     NPS Pharmaceuticals, Inc.                                                                                       55
     Nuvo Research Inc.                                                                                              55
     CombinatoRx, Incorporated                                                                                       56
     Torrent Pharmaceuticals Limited                                                                                 56
     Diamyd Medical AB                                                                                               57
     SCOLR Pharma, Inc.                                                                                              57
     Pluristem Therapeutics Inc.                                                                                     58
     DARA BioSciences, Inc.                                                                                          58
     Newron Pharmaceuticals S.p.A.                                                                                   59
     Angelini Group                                                                                                  59
     D-Pharm Ltd.                                                                                                    60
     Auspex Pharmaceuticals                                                                                          60
     VistaGen Therapeutics , Inc.                                                                                    61
     Palau Pharma S.A                                                                                                61
     Snowdon Inc.                                                                                                    62
     Neurotune AG                                                                                                    62
     Grunenthal GmbH                                                                                                 63
     Xenon Pharmaceuticals Inc.                                                                                      63
     Amura Holdings Ltd.                                                                                             64
     Affectis Pharmaceuticals AG                                                                                     64
     PharmEste                                                                                                       65
     Pharmascience Inc.                                                                                              65
     Arcion Therapeutics, Inc.                                                                                       66
     Solace Pharmaceuticals                                                                                          66
     Rottapharm SpA                                                                                                  67
     WEX Pharmaceuticals Inc.                                                                                        67
     Hydra Biosciences, Inc.                                                                                         68
     Yaupon Therapeutics, Inc.                                                                                       68
     NeurAxon, Inc.                                                                                                  69
     Virobay Inc.                                                                                                    69
     Concert Pharmaceuticals, Inc.                                                                                   70
     QRxPharma Limited                                                                                               70
     Cara Therapeutics, Inc.                                                                                         71
     Kalypsys, Inc.                                                                                                  71
     Bial Group                                                                                                      72
     KAI Pharmaceuticals Inc.                                                                                        72
     Winston Pharmaceuticals, Inc.                                                                                   73
     TheraQuest Biosciences, LLC                                                                                     73
     RaQualia Pharma Inc.                                                                                            74
     Mt Cook Pharma. Inc.                                                                                            74




Neuropathic Pain – Pipeline Review, H2 2011                                               GMDHC1320IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(3)
Neuropathic Pain – Pipeline Review, H2 2011


     SK Bio-Pharmaceuticals                                                                                          75
     Naurex, Inc.                                                                                                    75
Neuropathic Pain - Therapeutics Assessment                                                                           76
     Assessment by Monotherapy Products                                                                              76
     Assessment by Combination Products                                                                              77
     Assessment by Route of Administration                                                                           78
     Assessment by Molecule Type                                                                                     81
Late Stage Drug Profiles                                                                                             84
     Lyrica - Drug Profile                                                                                           84
          Product Description                                                                                        84
          Mechanism of Action                                                                                        84
          R&D Progress                                                                                               84
     AVP-923 - Drug Profile                                                                                          85
          Product Description                                                                                        85
          Mechanism of Action                                                                                        85
          R&D Progress                                                                                               85
     Sativex - Drug Profile                                                                                          86
          Product Description                                                                                        86
          Mechanism of Action                                                                                        86
          R&D Progress                                                                                               86
     Stedesa - Drug Profile                                                                                          88
          Product Description                                                                                        88
          Mechanism of Action                                                                                        88
          R&D Progress                                                                                               88
     BEMA Buprenorphine - Drug Profile                                                                               90
          Product Description                                                                                        90
          Mechanism of Action                                                                                        90
          R&D Progress                                                                                               90
     Amitriptyline - Drug Profile                                                                                    91
          Product Description                                                                                        91
          Mechanism of Action                                                                                        91
          R&D Progress                                                                                               91
     Pregabalin - Drug Profile                                                                                       92
          Product Description                                                                                        92
          Mechanism of Action                                                                                        92
          R&D Progress                                                                                               92
     Lidocaine - Drug Profile                                                                                        93
          Product Description                                                                                        93
          Mechanism of Action                                                                                        93
          R&D Progress                                                                                               93
     Lidocaine Patch - Drug Profile                                                                                  94
          Product Description                                                                                        94
          Mechanism of Action                                                                                        94
          R&D Progress                                                                                               94
     Pregabalin - Drug Profile                                                                                       96
          Product Description                                                                                        96
          Mechanism of Action                                                                                        96
          R&D Progress                                                                                               96




Neuropathic Pain – Pipeline Review, H2 2011                                               GMDHC1320IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(4)
Neuropathic Pain – Pipeline Review, H2 2011


     Pregabalin - Drug Profile                                                                                                          97
          Product Description                                                                                                          97
          Mechanism of Action                                                                                                          97
          R&D Progress                                                                                                                 97
     Amitriptyline + Ketamine + Lidocaine - Drug Profile                                                                                98
          Product Description                                                                                                          98
          Mechanism of Action                                                                                                          98
          R&D Progress                                                                                                                 98
     Sativex - Drug Profile                                                                                                            99
          Product Description                                                                                                          99
          Mechanism of Action                                                                                                          99
          R&D Progress                                                                                                                 99
     Paxil - Drug Profile                                                                                                              101
          Product Description                                                                                                          101
          Mechanism of Action                                                                                                          101
          R&D Progress                                                                                                                 101
     Varicella-Zoster Vaccine - Drug Profile                                                                                           102
          Product Description                                                                                                          102
          Mechanism of Action                                                                                                          102
          R&D Progress                                                                                                                 102
     Ketamine - Drug Profile                                                                                                           103
          Product Description                                                                                                          103
          Mechanism of Action                                                                                                          103
          R&D Progress                                                                                                                 103
     Botox - Drug Profile                                                                                                              104
          Product Description                                                                                                          104
          Mechanism of Action                                                                                                          104
          R&D Progress                                                                                                                 104
     JNS020QD - Drug Profile                                                                                                           105
          Product Description                                                                                                          105
          Mechanism of Action                                                                                                          105
          R&D Progress                                                                                                                 105
     NRI-ANA - Drug Profile                                                                                                            106
          Product Description                                                                                                          106
          Mechanism of Action                                                                                                          106
          R&D Progress                                                                                                                 106
Neuropathic Pain Therapeutics – Drug Profile Updates                                                                                   107
Neuropathic Pain Therapeutics - Discontinued Products                                                                                  112
     Neuropathic Pain - Featured News                                                                                                  114
          Sep 19, 2011: Spinifex Announces Start Of Phase II Proof-of-Concept Trial Of EMA401 In Postherpetic Neuralgia                114
          Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit       114
          Sep 13, 2011: BioLineRx Announces Positive Preliminary Results From Phase I Clinical Trial Of BL-1021 For Neuropathic Pain   115
          Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB
          Meeting                                                                                                                   116
          Sep 08, 2011: NeurogesX Submits Supplemental New Drug Application For Qutenza (capsaicin) 8% Patch For HIV-Associated Peripheral
          Neuropathy                                                                                                                   116
          Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced
          Neuropathic Pain In Patients With Cancer                                                                                 117
          Aug 09, 2011: GSK And XenoPort Submit Supplemental New Drug Application To FDA For Horizant In Postherpetic Neuralgia        118




Neuropathic Pain – Pipeline Review, H2 2011                                                         GMDHC1320IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                Page(5)
Neuropathic Pain – Pipeline Review, H2 2011


          Jul 25, 2011: Glenmark Completes Phase I Trial For GRC 15300 For Treatment Of Pain                                        118
          Jul 05, 2011: BioLineRx Announces Enrollment Of First Subject In Phase I Clinical Trial Of BL-1021 For Neuropathic Pain   118
          Jun 28, 2011: Nuvo Research Receives IND Clearance From FDA To Begin Clinical Testing Of Lidocaine Spray                  119
Appendix                                                                                                                            120
     Methodology                                                                                                                    120
          Coverage                                                                                                                  120
          Secondary Research                                                                                                        120
          Primary Research                                                                                                          120
          Expert Panel Validation                                                                                                   121
     Contact Us                                                                                                                     121
     Disclaimer                                                                                                                     121




Lis t o f Ta b le s
Number of Products Under Development for Neuropathic Pain, H2 2011                                                                   12

Products under Development for Neuropathic Pain – Comparative Analysis, H2 2011                                                      13

Number of Products under Development by Companies, H2 2011                                                                          15

Number of Products under Development by Companies, H2 2011                                                                          16

Number of Products under Development by Companies, H2 2011                                                                          17

Number of Products under Development by Companies, H2 2011                                                                          18

Number of Products under Investigation by Universities/Institutes, H2 2011                                                          20

Number of Products under Investigation by Universities/Institutes, H2 2011                                                          21

Number of Products under Investigation by Universities/Institutes, H2 2011                                                          22

Comparative Analysis by Late Stage Development, H2 2011                                                                             23

Comparative Analysis by Mid Clinical Stage Development, H2 2011                                                                      24

Comparative Analysis by Early Clinical Stage Development, H2 2011                                                                   25

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011                                                        26

Products under Development by Companies, H2 2011                               
				
DOCUMENT INFO
Description: Neuropathic Pain - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, H2 2011', provides an overview of the Neuropathic Pain therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. 'Neuropathic Pain - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Neuropathic Pain. - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries